NCT04884282
Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT04884282 |
| Title | Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED) (COMBI-TED) |
| Acronym | COMBI-TED |
| Recruitment | Unknown status |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | Yes |
| Sponsors | Fondazione Ricerca Traslazionale |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | ITA | FRA | ESP |
CKB BOOST